Mucosal immunology
Short-course intranasal LAT9997 therapy limits post-influenza bacterial pneumonia by recalibrating lung immunity.
Alison C West, Christopher M Harpur, Maggie Lam, Rebecca L Ambrose, Christopher Hodges, Stuart Mudge, David Kenley, Andrew J Gearing, Michelle D Tate
Published: 202610.1016/j.mucimm.2026.01.008
Abstract
Secondary bacterial pneumonia causes substantial morbidity and mortality following influenza A virus (IAV) infection, yet no therapies exist that address the underlying immune dysfunction and epithelial damage that predispose to bacterial superinfect…
Preview only. Read the full abstract at the source